Pharmacolog Appoints New Sales and Marketing Manager

Pharmacolog appoints Kent Öbrink as new Sales and Marketing Manager. Kent has more than 20 years of experience in qualified healthcare sales and a solid international experience. Kent will start on 1 of June and comes from C-Rad AB, where he held the role of Global Sales Manager.

As sales and marketing manager, Kent Öbrink will be responsible for the company’s commercial activities and for collecting important market intelligence before new development projects. Kent is a qualified microbiologist, but soon entered sales and marketing with a job as a Sales Representative at Kabi Pharmacia in 1991. After that, Kent held several qualified sales manager positions within the company until 1999, when he was recruited as sales manager at Fresenius-Kabi. For the past seven years, Kent has worked at C-Rad AB and has been instrumental in developing C-Rad’s sales and marketing organization. During the past four years, he has been acting as Global Sales Manager with responsibility for Europe and the United States.

CEO Mats Högberg comments. “With Kent at the helm of our sales and marketing activities, we are very well equipped to accelerate our commercial activities both internationally and nationally. Kent has a very relevant experience and competence profile for us. With his long experience of working with the sale of innovative technology in small and medium-sized companies in an international market, Kent will be a very valuable addition to our team of experts.”

Read the official press release (Swedish) here: Pharmacolog tillsätter ny sälj- och marknadschef

DrugLog® will be evaluated by a hospital chain in New York

Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.

Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in usi...

Nyemissionen registrerad

Pharmacolog i Uppsala AB (publ) har genomfört en nyemission med företrädesrätt för befintliga aktieägare med teckningstid 27 september – 13 oktober 2017 efter beslut av styrelsen den 28 augusti med stöd av bemyndigande från Bolagets årsstämma den 3 maj 2017. Emissionen, som övertecknades, tillförde Bolaget 19,6 MSEK före emissionskostnader.

Emissionen har registrerats av Bolagsverket den 1 november 2017. I samband med att emissionen har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA) att avregistreras och ersättas av nya aktier. Sista dag för handel med BTA på Aktietorget är den 6 november 2017.

Genom nyemissionen har aktiekapitalet i Pharmacolog ökat med 1 178 799,90 SEK...

Företrädesemissionen övertecknades till 150%

Teckningsperioden för Pharmacologs företrädesemission löpte ut den 13 oktober 2017 och det slutliga utfallet visar att den tecknades till 89,35 procent med stöd av teckningsrätter. Resterande del, motsvarande 10,65 procent, har tecknats utan stöd av teckningsrätter. Företrädesemissionen är därmed fulltecknad och tillför Bolaget cirka 19,6 MSEK före emissionskostnader. Sammanlagt tecknades Företrädesemissionen till drygt 150 procent.

Totalt tecknades 3 510 991 aktier med stöd av teckningsrätter, motsvarande cirka 17,6 MSEK eller 89,35 procent av Företrädesemissionen. Resterande 418 342 aktier, motsvarande cirka 2,1 MSEK eller 10,65 procent av Företrädesemissionen, har tilldelats personer som teckn...

New analysis of Pharmacolog

New company analysis of Pharmacolog AB performed by Jarl Securities. Read the complete analysis here (in Swedish only): https://www.aktiespararna.se/sites/default/files/phlog_2017-09-28.pdf